A new Pfizer Animal Health was unveiled last week as Pfizer’s acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed.

The acquisition of many of Fort Dodge’s U.S. products allows Pfizer Animal Health to greatly diversify its U.S. portfolio, as well as broaden its offering in all animal health segments. Pfizer Animal Health now offers an enhanced portfolio in beef, dairy, and companion animals, as well as a redefined product line for swine, equine, and poultry.

Pfizer’s equine brands such as Strongid (pyrantel pamoate), Dormosedan (detomidine hydrochloride), and Hylartin (sodium hyaluronate) are joined by Fort Dodge’s West Nile Innovator, Fluvac Innovator, and Quest (moxidectin), and Quest Plus (moxidectin/praziquantel).

“We’re extremely proud to offer our customers even more best-in-class and innovative products,” said Clint Lewis, president of U.S Operations for Pfizer Animal Health. “The products, services and expertise we are gaining strengthen what is already a robust U.S. portfolio and will enhance our leading position in the animal health marketplace